Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Down 21.5% in April

Spero Therapeutics, Inc. (NASDAQ:SPRO) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 513,200 shares, a decrease of 21.5% from the March 31st total of 653,800 shares. Based on an average daily volume of 321,500 shares, the short-interest ratio is currently 1.6 days.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SPRO. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Spero Therapeutics in a report on Monday, March 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Thursday, April 4th.

Institutional Trading of Spero Therapeutics

A hedge fund recently raised its stake in Spero Therapeutics stock. Acadian Asset Management LLC increased its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 56.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 272,024 shares of the company’s stock after acquiring an additional 98,485 shares during the quarter. Acadian Asset Management LLC owned approximately 0.52% of Spero Therapeutics worth $327,000 as of its most recent SEC filing. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Stock Down 1.4 %

NASDAQ:SPRO traded down $0.02 during mid-day trading on Tuesday, reaching $1.42. The company’s stock had a trading volume of 95,313 shares, compared to its average volume of 288,410. Spero Therapeutics has a 1 year low of $0.99 and a 1 year high of $2.00. The stock has a fifty day moving average of $1.63 and a 200-day moving average of $1.43. The firm has a market capitalization of $76.52 million, a PE ratio of 3.38 and a beta of 0.55.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Wednesday, March 13th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $1.14. Spero Therapeutics had a net margin of 21.98% and a return on equity of 38.54%. The company had revenue of $73.52 million during the quarter, compared to analyst estimates of $19.40 million. On average, analysts expect that Spero Therapeutics will post -0.94 earnings per share for the current year.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.